Epoprostenol and Iloprost share 4 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.444 means 44% of the combined target set is bound by both compounds. The IDF-weighted score of 0.434 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Epoprostenol and Iloprost have in common?
Epoprostenol and Iloprost share 4 molecular targets with a Jaccard similarity of 44%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Epoprostenol and Iloprost be combined?
Epoprostenol and Iloprost share 4 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Epoprostenol or Iloprost?
In the BiohacksAI corpus: Epoprostenol has 297 PubMed-indexed studies, Iloprost has 300 studies.